Roca Neus, Jatem Elias, Abo Anabel, Santacana Maria, Cruz Alejandro, Madrid Álvaro, Fraga Gloria, Martin Marisa, Gonzalez Jorge, Martinez Cristina, Balius Anna, Segarra Alfons
Servicio Nefrologia Pediátrica, Hospital Universitari de Vic, Universitat de Vic, Barcelona, Spain.
Servicio de Nefrologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Clin Kidney J. 2021 Nov 15;15(3):545-552. doi: 10.1093/ckj/sfab215. eCollection 2022 Mar.
Activation of parietal-epithelial cells (PECs) with neo-expression of CD44 has been found to play a relevant role in the development of focal and segmental glomerulosclerosis (FSGS). The aim of this study was to analyse whether the expression of CD44 by PECs in biopsies of minimal change disease (MCD) is associated with the response to corticosteroids, with kidney outcomes and/or can be considered an early sign of FSGS.
This multicentric, retrospective study included paediatric and adult patients with MCD. Demographic, clinical and biochemical data were recorded, and biopsies were stained with anti-CD44 antibodies. The association between PECs, CD44 expression and the response to corticosteroids, and kidney outcomes were analysed using logistic, Kaplan-Meier and Cox regression analyses.
A total of 54 patients were included: 35 (65%) <18 years and 19 (35%) adults. Mean follow-up was 68.3 ± 37.9 months. A total of 19/54 patients (35.2%) showed CD44-positive staining. CD44-positive patients were younger (14.5 ± 5 versus 21.5 ± 13, P = 0.006), and showed a higher incidence of steroid-resistance [11/19 (57.8%) versus 7/35 (20%), P = 0.021; odds ratio: 5.5 (95% confidence interval 1.6-18), P = 0.007] and chronic kidney disease [9/19 (47.3%) versus 6/35 (17.1%), P = 0.021; relative risk: 3.01 (95% confidence interval 1.07-8.5), P = 0.037]. Follow-up re-biopsies of native kidneys ( = 18), identified FSGS lesions in 10/12 (83.3%) of first-biopsy CD44-positive patients versus 1/6 (16.7%) of first-biopsy CD44-negative patients (P = 0.026).
In patients with a light microscopy pattern of MCD, CD44-positive staining of PECs is associated with a higher prevalence of steroid resistance and worse kidney outcomes, and can be considered an early sign of FSGS.
已发现伴有新表达CD44的壁层上皮细胞(PEC)激活在局灶节段性肾小球硬化(FSGS)的发展中起相关作用。本研究的目的是分析微小病变病(MCD)活检中PEC的CD44表达是否与对皮质类固醇的反应、肾脏预后相关,和/或是否可被视为FSGS的早期迹象。
这项多中心回顾性研究纳入了患有MCD的儿科和成年患者。记录人口统计学、临床和生化数据,并用抗CD44抗体对活检组织进行染色。使用逻辑回归、Kaplan-Meier和Cox回归分析来分析PEC、CD44表达与对皮质类固醇的反应以及肾脏预后之间的关联。
共纳入54例患者:35例(65%)年龄<18岁,19例(35%)为成年人。平均随访时间为68.3±37.9个月。共有19/54例患者(35.2%)表现为CD44阳性染色。CD44阳性患者更年轻(14.5±5岁对21.5±13岁,P = 0.006),并且表现出更高的类固醇抵抗发生率[11/19例(57.8%)对7/35例(20%),P = 0.021;比值比:5.5(95%置信区间1.6 - 18),P = 0.007]和慢性肾脏病发生率[9/19例(47.3%)对6/35例(17.1%),P = 0.021;相对风险:3.01(95%置信区间1.07 - 8.5),P = 0.037]。对天然肾进行随访再活检(n = 18),在首次活检CD44阳性患者中有10/12例(83.3%)发现FSGS病变,而在首次活检CD44阴性患者中有1/6例(16.7%)发现(P = 0.026)。
在具有MCD光学显微镜表现的患者中,PEC的CD44阳性染色与更高的类固醇抵抗患病率和更差的肾脏预后相关,并且可被视为FSGS的早期迹象。